AUPH · Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

#140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, Canada
Biotechnology
Healthcare

Market Cap

2.064B

52 Wk Range

$13.52 - $19.25

Previous Close

$15.40

Open

$15.30

Volume

170,891

Day Range

$15.11 - $15.45

Enterprise Value

1.635B

Cash

486.9M

Avg Qtr Burn

N/A

Insider Ownership

6.74%

Institutional Own.

60.12%

Qtr Updated

Sep 30th 2026